Showing results (41-50 of 54) with videos related to
Sort By:
Pageof 6
The Lancet. Oncology|September 5, 2020
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trialNathalie Baize, Isabelle Monnet, Laurent Greillier, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 StudyRomain Corre, Laurent Greillier, Hervé Le Caër, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2017
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung CancerJames Chih-Hsin Yang, Sai-Hong Ignatius Ou, Luigi De Petris, et al.Lancet (London, England)|August 12, 2011
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trialElisabeth Quoix, Gérard Zalcman, Jean-Philippe Oster, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2015
Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II StudyBenjamin Besse, Sylvestre Le Moulec, Julien Mazières, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2016
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung CancerShirish M Gadgeel, Alice T Shaw, Ramaswamy Govindan, et al.Nature Medicine|August 22, 2022
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trialSolange Peters, Rafal Dziadziuszko, Alessandro Morabito, et al.Oncoimmunology|May 4, 2016
Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLCBenjamin Besse, Mélinda Charrier, Valérie Lapierre, et al.The European Respiratory Journal|August 12, 2017
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patientsMyriam Delaunay, Jacques Cadranel, Amélie Lusque, et al.The Lancet. Oncology|December 17, 2021
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trialCecile Le Pechoux, Nicolas Pourel, Fabrice Barlesi, et al.Pageof 6